Top

Open Access 27-03-2024 | Graft-Versus-Host Disease | Original Article

Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis

Authors: Mary Jo Lechowicz, Christy Smith, Robert Ristuccia, Karen Dwyer

Published in: International Journal of Hematology

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL). Mogamulizumab is an anti-CCR4 antibody that has been associated with an increased risk of transplant-related complications in retrospective analyses of ATL, particularly when administered within 50 days before transplantation. This post hoc analysis of 3 clinical trials examined safety and outcome data for 32 patients with CTCL (n = 23), ATL (n = 7), or PTCL (n = 2) who underwent allo-HSCT after mogamulizumab treatment. Overall, 22 patients (69%) were known to have graft-versus-host disease (GVHD), 8 patients (25%) did not report GVHD, and 2 patients (6%) had unknown GVHD status. Fourteen patients with known GVHD underwent transplantation between 50 and 365 days after their last dose of mogamulizumab, while 2 underwent transplantation within 50 days after treatment. Based on this limited evidence, GVHD was not associated with the time interval from last mogamulizumab dose to transplantation.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel). 2021;9(1):5. https://doi.org/10.3390/medsci9010005.CrossRefPubMed

Phan A, Veldman R, Lechowicz MJ. T-cell lymphoma epidemiology: the known and unknown. Curr Hematol Malig Rep. 2016;11(6):492–503. https://doi.org/10.1007/s11899-016-0353-y.CrossRefPubMed

Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood. 2018;132(3):245–53. https://doi.org/10.1182/blood-2018-01-791335.CrossRefPubMed

Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas. Cancers (Basel). 2020;12(10):2856. https://doi.org/10.3390/cancers12102856.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204. https://doi.org/10.1016/S1470-2045(18)30379-6.CrossRefPubMed

Zhang T, Sun J, Li J, Zhao Y, Zhang T, Yang R, et al. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies. BMC Cancer. 2021;21(1):618. https://doi.org/10.1186/s12885-021-08363-w.CrossRefPubMedPubMedCentral

POTELIGEO. Prescribing information. Kyowa Kirin, Inc; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761051s015lbl.pdf. Accessed 28 June 2023.

Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–33. https://doi.org/10.1200/JCO.2016.67.8250.CrossRefPubMed

10.

Kamada Y, Arima N, Hayashida M, Nakamura D, Yoshimitsu M, Ishitsuka K. Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab. Leuk Lymphoma. 2022:1701–7. https://doi.org/10.1080/10428194.2022.2043300.

11.

Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, et al. A multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(1):23-30.e22. https://doi.org/10.1016/j.clml.2016.09.009.CrossRefPubMed

12.

Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant. 2016;51(5):725–7. https://doi.org/10.1038/bmt.2015.315.CrossRefPubMed

13.

Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(9):1608–14. https://doi.org/10.1016/j.bbmt.2016.05.017.CrossRefPubMed

14.

Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau MED, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica. 2016;101(10):e407–10. https://doi.org/10.3324/haematol.2016.146977.CrossRefPubMedPubMedCentral

15.

Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2019;104(5):993–1003. https://doi.org/10.3324/haematol.2018.205096.CrossRefPubMedPubMedCentral

16.

Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42. https://doi.org/10.1200/JCO.2011.37.3472.CrossRefPubMed

17.

Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, et al. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant. 2013;19(12):1731–9. https://doi.org/10.1016/j.bbmt.2013.09.014.CrossRefPubMed

18.

Huang W-R, Liu D-H. Peripheral T-cell lymphomas: updates in allogeneic hematopoietic stem cell transplantation. Chin Med J (Engl). 2018;131(17):2105–11. https://doi.org/10.4103/0366-6999.239315.CrossRefPubMed

19.

Angelov D, Dillon J, Mellerick L, Pender E, Bacon L, Lee G, et al. Allogeneic transplantation in cutaneous T-cell lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease. Bone Marrow Transplant. 2022;57(8):1332–4. https://doi.org/10.1038/s41409-022-01713-7.CrossRefPubMed

20.

Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–9. https://doi.org/10.1200/JCO.2010.29.3241.CrossRefPubMed

21.

Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56(6):1391–401. https://doi.org/10.1038/s41409-020-01197-3.

22.

Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sézary syndrome. Bone Marrow Transplant. 2014;49(11):1360–5. https://doi.org/10.1038/bmt.2014.161.CrossRefPubMedPubMedCentral

23.

Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematol Oncol. 2020;38(3):266–71. https://doi.org/10.1002/hon.2719.CrossRefPubMed

24.

Weng W-K, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020;4(18):4474–82. https://doi.org/10.1182/bloodadvances.2020001627.CrossRefPubMedPubMedCentral

Title: Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis
Authors: Mary Jo Lechowicz
Christy Smith
Robert Ristuccia
Karen Dwyer
Publication date: 27-03-2024
Publisher: Springer Nature Singapore
Keywords: Graft-Versus-Host Disease
Graft-Versus-Host Disease
Lymphoma
Mycosis Fungoides
Sézary Syndrome
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-024-03753-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer